{"slideshow_credits": null, "snippet": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes.", "abstract": "Eli Lilly says it is stopping development of drug for cardiovascular disease because drug is not likely to be determined effective in preventing heart attacks and strokes.", "section_name": "Business Day", "print_page": "4", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK"}, "web_url": "http://www.nytimes.com/2015/10/13/business/eli-lilly-abandons-heart-disease-drug-in-final-stages-of-trials.html", "lead_paragraph": "The drug was expected to be a blockbuster, but its maker said it was not likely to be found effective in preventing heart attacks and strokes.", "headline": {"main": "Eli Lilly Abandons Heart Disease Drug in Final Stage of Trials", "print_headline": "Lilly Drops Heart Drug in Last Stage of Its Trials"}, "_id": "561bb5df38f0d839bd911198", "word_count": "722", "multimedia": [], "pub_date": "2015-10-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Eli Lilly and Company", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Heart", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Cholesterol", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": null, "type_of_material": "News"}